Home / Biopharma / EPS Estimates Lure Passive Investments: Celgene Corporation (NASDAQ:CELG), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

EPS Estimates Lure Passive Investments: Celgene Corporation (NASDAQ:CELG), Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Celgene Corporation (NASDAQ:CELG) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -2.96% to close at $118.51 with the total traded volume of 5.48 Million shares. Finally, analysts shed their light over the CELG price targets; maintaining price high target of 162.00 while at average the price target was 137.92 in contrast with the current price of 118.51. The price targets are usually acts as the boosters or blasters in the performance of stock. A higher price target would definitely provide confidence to investors during the trading action, consideration given by Wall Street Journal.

So does the rankings given by analysts; let us highlight rankings table and we had 24 analysts recommending BUY ratings for current month and for previous month 21 stands on similar situation; while 4 for the current month as compared to 4 analysts recommending for HOLD from the pool for previous month. While 1 stands at overweight and 1 out of pool consider it as Sell for current month. For the overall, consensus ratings were for Buy.

The firm has institutional ownership of 77.90%, while insider ownership included 0.20%. Its price to sales ratio ended at 8.50. CELG attains analyst recommendation of 1.80 with week performance of -2.03%.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) [Trend Analysis] moved down reacts as active mover, shares a decrease -5.42% to traded at $43.76 and the percentage gap between open changing to regular change was -1.06%. Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have ranked IONS in recent few months. In ratings table the IONS given BUY ratings by 5 analysts in current phase. The 1 number of analyst/s have SELL recommendation for current month on IONS. While 7 number of analysts gave ratings for HOLD in current. As per remarks given by WSJ, overall consensus pool recommend it as Overweight security.

The stock was assessed in terms of profitability as current quarter EPS estimate trends showed $-0.16 at current month while compared with $-0.12 in a month ago. The stock next year first quarter current estimate trend for EPS was for $-0.27 and on annual basis FY 2016 estimate trends at current was for $-1.12 as compared to one month ago of $-1.13, and for next year per share earnings estimates have $-0.98.

The firm’s current ratio calculated as 6.80 for the most recent quarter. The firm past twelve months price to sales ratio was 22.30 and price to cash ratio remained 7.61. As far as the returns are concern, the return on equity was recorded as -120.60% and return on investment was -11.30% while its return on asset stayed at -21.10%. The firm has total debt to equity ratio measured as 3.55.

 

About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Check Also

Stock Revamps on Eco Changes: Alexion Pharmaceuticals (NASDAQ:ALXN), Novartis (NYSE:NVS)

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) [Trend Analysis] swings enthusiastically in regular trading session, it a gain …

Leave a Reply

Your email address will not be published. Required fields are marked *